Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 09/26 02:18:08 pm
67.655 EUR   -1.16%
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for ..
07:01a SANOFI : and Regeneron Announce Dupilumab Biologics License Applicat..
07:01a SANOFI : Regeneron and Sanofi Announce Dupilumab Biologics License A..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : Former Sanofi employees convicted of bribery in Germany

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/03/2014 | 07:24pm CEST

A German court convicted two former employees of Sanofi-Aventis on bribery charges 10 months ago and imposed a fine on the French drugmaker last year, prosecutors said on Monday following a newspaper report.

News of the 28 million euro ($39 million) fine coincides with heightened scrutiny of Big Pharma's sales practices after a bribery scandal in China hit business there last year.

Further investigations are ongoing, a spokesman for prosecutors in the northern German town of Verden said, confirming a report by German daily newspaper Frankfurter Allgemeine Zeitung, but they declined to say whether these were related to Sanofi or to its employees.

The spokesman said an investigation of the former Sanofi employees found that they had made illicit payments to a consultancy advising one of the drugmaker's clients between 2007 and 2010 to win more orders from the client, a pharmaceuticals dealer.

"Sanofi was unfairly given preference because of this," he said.

He declined to provide details on who the client was or which markets it operated in. He also did not name the former Sanofi employees or the consultant.

A court in the town of Winsen handed the two former employees of Sanofi suspended sentences for bribery in business transactions in May 2013, the spokesman said. They both worked with Sanofi's sales force and were not senior managers.

The Winsen court also ordered that punishment be meted out to the owner of the consultancy, but that judgment was not yet final due to a pending complaint against the ruling.

The bribery investigation has not come to light until now because the suspects were sentenced via a simplified legal process that under German law allows courts to try some crimes without a courtroom trial.

The court's ruling also resulted in a 28 million euro fine for Sanofi. A spokeswoman for Sanofi-Aventis Deutschland GmbH confirmed the company had to pay that sum in connection with the case against the two former employees.

"For Sanofi the matter is closed," the spokeswoman said, referring to the Winsen court's rulings. She added the company had cooperated with authorities during the investigation and had since further tightened its compliance system.

Sanofi acquired Aventis in 2004, creating Sanofi-Aventis. In 2011, the company simplified its name to Sanofi.

(Reporting by Maria Sheahan and Frank Siebelt; Additional reporting by Natalie Huet in Paris; Writing by Marilyn Gerlach; editing by Mike Collett-White)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
07:01a SANOFI : and Regeneron Announce Dupilumab Biologics License Application Accepted..
07:01a SANOFI : Regeneron and Sanofi Announce Dupilumab Biologics License Application A..
09/21 SANOFI : Files Suit in U.S. to Defend Patent Rights on Lantus and Lantus Solosta..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 Indian pharma firms in global alliance to fight drug resistance
09/20 SANOFI : Losing steam in the war vs dengue
09/20 SANOFI : Files Suit in U.S. to Defend Patent Rightson Lantus and Lantus Solostar
09/20DJBusiness Watch -- WSJ
09/19 SANOFI : Treatment Effects Maintained Over Six Years in Patients with Relapsing ..
More news
Sector news : Pharmaceuticals - NEC
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
01:46p Pfizer abandons plan to split into two
06:57aDJPFIZER : Won't Pursue a Split
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06:58a FDA accepts dupilumab BLA for review; action date March 29, 2017
03:16a MANNKIND : Afrezza Scripts Approach 300; Trajectory Is Still Low
01:50a Amgen's New Products Have Ample Insurance Coverage In The U.S.
09/24 BIOTECH : What's Next For M&A?
09/23 Priority Review Vouchers Revisited
Advertisement
Financials (€)
Sales 2016 36 923 M
EBIT 2016 9 287 M
Net income 2016 5 275 M
Debt 2016 5 441 M
Yield 2016 4,30%
P/E ratio 2016 15,70
P/E ratio 2017 14,39
EV / Sales 2016 2,54x
EV / Sales 2017 2,54x
Capitalization 88 235 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 82,8 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-12.91%99 053
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results